Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOST: IVIg in HSCT for Multiple Sclerosis
NCT03342638Phase 3Terminated
- Sponsor
- Northwestern University
- Start
- Nov 2017
- Primary completion
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of intravenous immunoglobulin G in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Northwestern University. Primary endpoint: Rate of Disease Activity at 5 years. Started Nov 2017; status: terminated.
02
Drugs
intravenous immunoglobulin G
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT03342638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03342638.